HeartSciences (NASDAQ:HSCS) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of HeartSciences (NASDAQ:HSCS) from a sell rating to a hold rating in a research report sent to investors on Sunday,Wall Street Zen reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of HeartSciences in a report on Wednesday, June 24th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $8.00.

HeartSciences Stock Performance

Shares of HSCS stock opened at $5.20 on Friday. The firm has a market capitalization of $24.96 million, a PE ratio of -1.61 and a beta of 1.85. The firm has a fifty day simple moving average of $2.81 and a two-hundred day simple moving average of $2.43. HeartSciences has a 12 month low of $1.63 and a 12 month high of $5.21.

HeartSciences (NASDAQ:HSCS) last released its quarterly earnings data on Monday, September 14th. The company reported ($0.86) earnings per share for the quarter, missing the consensus estimate of ($0.72) by ($0.14). The business had revenue of $0.00 million for the quarter, compared to analysts’ expectations of $0.10 million. On average, equities analysts predict that HeartSciences will post -2.99 earnings per share for the current fiscal year.

HeartSciences News Roundup

Here are the key news stories impacting HeartSciences this week:

• Positive Sentiment: Wall Street Zen upgraded HeartSciences, providing a potential sentiment boost for the medical-device company. The specific rating change was not detailed in the available report. HeartSciences Upgraded at Wall Street Zen
• Positive Sentiment: Maxim Group raised its earnings forecasts across 2027 and 2028. The firm lifted its FY2027 EPS estimate to a loss of $2.88 from $2.98 and its FY2028 estimate to a loss of $2.01 from $2.13. Quarterly estimates were also revised higher, including Q2 2027 to a loss of $0.72 from $0.75 and Q3 2027 to a loss of $0.70 from $0.75.
• Positive Sentiment: The revisions suggest Maxim expects HeartSciences’ losses to narrow more quickly than previously anticipated, with later-quarter estimates also improving: Q1 2028 to a loss of $0.65, Q2 2028 to $0.61, Q3 2028 to $0.46 and Q4 2028 to $0.32 per share.
• Neutral Sentiment: Despite the improved outlook, HeartSciences is still expected to report significant losses. The current-year consensus estimate remains a loss of approximately $3.04 per share, while the company previously reported no quarterly revenue and missed its latest EPS estimate.

HeartSciences Company Profile

HeartSciences, Inc is a medical technology company focused on improving the detection and management of cardiovascular disease. The company develops electrocardiography (ECG) technologies intended to provide clinicians with additional information about cardiac function using a test that is widely available in healthcare settings.

Its principal technology is the MyoVista wavECG system, which applies proprietary signal-processing methods, including wavelet analysis, to standard 12-lead ECG data.